期刊文献+

转人内皮抑素基因双歧杆菌液抑制血管生长的实验观察 被引量:3

Transgenic bifidobacterial suspension of endostatin in inhibiting angiogenesis:an experimental observation
暂未订购
导出
摘要 目的 :研究转人内皮抑素基因双歧杆菌液对血管生长的抑制作用 ,并观察其对动物移植性肝癌Heps的抑瘤作用。 方法 :以小鼠移植性肝癌Heps建立肿瘤模型 ;分别进行灌胃和尾静脉注射给药 ,同时用转人内皮抑素基因双歧杆菌液做鸡胚绒毛尿囊膜 (CAM )实验 ,在解剖显微镜下计数血管条数 ,用图像分析仪定量分析血管密度。实验动物处死后 ,称瘤重并计算抑瘤率。结果 :转基因双歧杆菌液高、中、低 3个剂量组的抑瘤率分别为 49.78%、45 .81%和 30 .41%;普通双歧杆菌组抑瘤率为10 .9%,尾静脉注射转基因双歧杆菌组抑瘤率为 5 8.3%;CAM实验显示转基因双歧杆菌液可明显抑制血管的生成。结论 :转基因双歧杆菌有良好的抑制血管生长和抑制肿瘤生长的作用 ,且其作用有量效关系。 Objective: To study the inhibitory effect of transgenic bifidobacterial suspension of endostatin on angiogenesis and to observe its inhibitory effect on animal transplant liver cancer Heps. Methods: After the model of transplant liver cancer Heps in mice was established, transgenic bifidobacteria was given by stomach-drenching and was injected into the tumor-bearing mice via their tail veins. At the same time, the experiment of chorioallantoic membrane (CAM) was practiced by using transgenic bifidobacterial suspension of endostatin. The numbers of capillary of CAM were counted under an anatomical microscope and the density of microvessels was analyzed quantitatively by imaging analysis apparatus. After the mice were killed, the tumors of the mice were weighed and the tumor inhibitory rate were counted. Results: The tumor inhibitory rates of the transgenic bifidobacterial suspension in groups of high, medium and low dose groups were 49.78%, 45.81%, 30.41%, respectively. The tumor inhibitory rate in the group of normal bifidobacterial suspension was 10.9%, and the tumor inhibitory rate in the group of transgenic bifidobacterial suspension of endostatin injected via tail vein was 58.3%. The experiment of CAM shows that transgenic bifidobacterial suspension of endostatin can significantly inhibit angiogenesis. Conclusion: Transgenic bifidobacteria of endostatin has good effect in inhibiting angiogenesis and tumor growth, and its effect is dose-dependent.
出处 《南京军医学院学报》 2002年第2期75-77,共3页 Journal of Nanjing Military Medical College
关键词 转人内皮抑素基因 双歧杆菌液 血管生长 实验观察 肿瘤 小鼠 transgene endostatin bifidobacteria tumors chorioallantoic membrane mice
  • 相关文献

参考文献5

二级参考文献11

  • 1Nelson NJ. Inhibitors of angiogenesis enter phase Ⅲ testing. J Natl Cancer Inst, 1998, 90: 960~963.
  • 2徐根兴,任敏东,许琳.发明专利公告:转人体内皮抑素基因双歧杆菌的方法.1998,14:45.CN1177005
  • 3Boehm T, Folkman J, Browder T, O′Reilly MS.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature,1997, 390: 404~407.
  • 4Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol, 1995,147: 9~19.
  • 5Folkman J, D′Amore PA. Blood vessel formation:what is its molecular basis? Cell, 1996, 87: 1153~1155.
  • 6O′Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR,Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88:277~285.
  • 7Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP. Endosatatin induces endothelial cell apoptosis. J Biol Chem, 1999, 274: 11721~11726.
  • 8陆良勇,陈成伟,刘燕,傅青春,倪鎏达.运用原位末端标记和ICM—DNA定量检测重型肝炎中Ⅲ型细胞死亡[J].肝脏,1999,4(2):70-72. 被引量:2
  • 9上海医学会学术会务部,上海医学会肺科学会中青年学组.肺癌多学科治疗现状及进展研讨会纪要[J].中华结核和呼吸杂志,1999,22(9):520-522. 被引量:5
  • 10孙燕.国外食管癌化学治疗和综合治疗的进展[J].当代医学,1995,4(1):13-15. 被引量:1

共引文献19

同被引文献43

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部